IMUC Demonstrates Impressive Survival Data Print E-mail
By Staff and Wire Reports   
Wednesday, 02 June 2010 08:19

As subscribers to BioMedReports were alerted yesterday, a therapeutic brain cancer vaccine developed by ImmunoCellular Therapeutics Ltd (IMUC.OB) has shown that nearly half the patients were alive without their cancer worsening 18 months after diagnosis.



ImmunoCellular Therapeutics' ICT-107 Demonstrates 80 Percent Survival at 2 Years in Phase I Study of Newly Diagnosed Glioblastoma Patients

The company said on Wednesday that the data comes from the Phase 1 trial from ImmunoCellular involved patients diagnosed with glioblastoma multiforme, the most common and deadly form of brain cancer.

They were treated with ICT-107, an experimental dendritic cell based cancer vaccine, following the standard care of surgery, radiation and chemotherapy.

"We are targeting specific antigens that are on cancer stem cells ... the only population of cells that can really propagate a tumor," said Dr. John Yu, director of surgical neuro-oncology at Cedars-Sinai Medical Center in Los Angeles and ImmunoCellular's chief scientific officer.

A year after diagnosis, all of the patients were alive. After two years, 80 percent of them were alive.

Historically, after a year with standard treatment, 61 percent of glioblastoma patients are alive, and 26.5 are alive after two years, according to the company.

“These new data further establish ICT-107 as a promising potential treatment for glioblastoma, a disease for which there are currently few and limited treatment options,” said Surasak Phuphanich, M.D., Director of the Neuro-Oncology Program at Cedars-Sinai Medical Center. “We are excited for what these data mean for patients, the medical community, and the field of immunotherapy as a whole. We look forward to further investigating ICT-107 in additional clinical studies.”

In the ImmunoCellular trial, median overall survival had not yet been reached at the 26.4 months analysis point, with 12 out of 16 patients alive. Seven patients continued to live with no disease progression.

 

Yu said ImmunCellular is planning a mid-stage trial of the vaccine that would include between 30 and 50 patients.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter